Bloom Olivia Kyusuk
Known title: DirectorCIK: 0001501545
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
GERN Highlights Imetelstat at International Hematology Congresses. Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.
Transaction History
| PSNL | ▲ Buy | Grant | 6,250 | $0 | 5/12/2026 | View on chart |
| GERN | ▲ Buy | Option Exercise | 400,000 | $604K | 2/8/2023 | View on chart |
| GERN | ▼ Sell | Open Market | 400,000 | $1.2M | 2/8/2023 | View on chart |
| PSNL | ▲ Buy | Grant | 10,770 | $0 | 5/17/2022 | View on chart |
| PSNL | ▲ Buy | Grant | 10,245 | $0 | 3/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Competitors Tempus and Natera draw market attention
Recent news highlights increased activity by Personalis competitors. Tempus AI is expanding its cancer vaccine infrastructure with Moderna and Merck, while Natera faces rising competitive threats. These developments underscore the crowded nature of the precision medicine sector, providing context for Personalis's current trading position near its support levels.
Competitors Tempus and Natera draw market attention. Recent news highlights increased activity by Personalis competitors. Tempus AI is expanding its cancer vaccine infrastructure with Moderna and Merck, while Natera faces rising competitive threats. These developments underscore the crowded nature of the precision medicine sector, providing context for Personalis's current trading position near its support levels.